Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Breast Diseases 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

exemestane 7Trastuzumab 7Anastrozole 7Letrozole 6Docetaxel 6palbociclib 5pyrotinib 4entinostat 4Fulvestrant 4Cyclophosphamide 4ribociclib 3abemaciclib 3Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Aromatase Inhibitors 2AZD9833 2trastuzumab deruxtecan 1taxane 1sacubitril and valsartan sodium hydrate drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Diseases × Imlunestrant × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡